Pfizer Cash Flow from Operating Activities 2010-2024 | PFE
Pfizer annual/quarterly cash flow from operating activities history and growth rate from 2010 to 2024. Cash flow from operating activities can be defined as a company's cash flows from operations.
- Pfizer cash flow from operating activities for the quarter ending December 31, 2024 was $12.744B, a 46.48% increase year-over-year.
- Pfizer cash flow from operating activities for the twelve months ending December 31, 2024 was $19.166B, a 43.29% increase year-over-year.
- Pfizer annual cash flow from operating activities for 2024 was $12.744B, a 46.48% increase from 2023.
- Pfizer annual cash flow from operating activities for 2023 was $8.7B, a 70.27% decline from 2022.
- Pfizer annual cash flow from operating activities for 2022 was $29.267B, a 10.17% decline from 2021.
Pfizer Annual Cash Flow Ops
(Millions of US $) |
| 2024 |
$12,744 |
| 2023 |
$8,700 |
| 2022 |
$29,267 |
| 2021 |
$32,580 |
| 2020 |
$14,403 |
| 2019 |
$12,588 |
| 2018 |
$15,827 |
| 2017 |
$16,802 |
| 2016 |
$16,192 |
| 2015 |
$14,688 |
| 2014 |
$17,084 |
| 2013 |
$17,684 |
| 2012 |
$16,746 |
| 2011 |
$20,240 |
| 2010 |
$11,454 |
| 2009 |
$16,587 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$151.025B |
$63.627B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
